Background
De-Chao Yu was born on February 4, 1964 in Tiantai, Zhejiang, China. Son of Jihe Yu and Liangmei Yee.
- Photos
- Works
- Photos
- Works
DeChao Yu
Edit Profile俞德超
also known as
Michael Yu
Education
De-Chao Yu received Doctor of philosophy degree in Genetics from the Chinese Academy of Sciences and completed post-doctoral training in pharmaceutical chemistry at the UCSF.
Career
De-Chao Yu was a co-founder, President and CEO of Chengdu Kanghong Biotech from 2006 to 2010, and the vice president of Research and Development at Applied Genetic Technologies Corporation (NASDAQ: AGTC) and Calydon, Inc. In 2011, he founded Innovent Biologics. De-Chao Yu is a professor and doctoral supervisor of Sichuan University, a visiting professor of Zhejiang University and an adjunct professor at Suzhou University, the chairman of the board of the Chinese Antibody Society cific virus for treatments of prostate cancer.
Achievements
-
DeChao Yu invented and developed three "Class I" drugs in China. He invented Conbercept, which is China's first monoclonal antibody product; Oncorine (an oncology product), which is the world's first oncolytic virus product; Tyvyt (generic name: sintilimab), which is the domestically developed PD-1 antibody jointly developed by Innovent Biologics and Eli Lilly and Company, and the key clinical results of Tyvyt in patients with r/r cHL have been published by the Lancet Haematology. And Tyvyt has been officially approved by the National Medical Products Administration of China for marketing in China for relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL) as the first approved indication.
